Cleveland Biolabs Inc (NASDAQ:CBLI) Sentiment Dropped to 1, Despite

May 16, 2018 - By Alma Kearns

Cleveland BioLabs, Inc. (NASDAQ:CBLI) Corporate Logo

Cleveland Biolabs Inc’s Sentiment

“Big money sentiment for Cleveland Biolabs Inc (NASDAQ:CBLI) in 2017 Q4 decreased to 1, according to SEC filings. That’s down -0.50, from 2017Q3’s 1.5. 5 hedge funds increased or started new holdings, while 5 reduced and sold their equity positions in Cleveland Biolabs Inc so the sentiment fall. Funds own 441,233 shares, up from 438,124 shares in 2017Q3. Funds holding Cleveland Biolabs Inc in top 10 changed to 0 from 0 for the same number . 2 Investors Sold All; 3 Reduced Holdings; 2 increased stakes while 3 hedge funds bought stakes.

Most Cleveland Biolabs Inc Investors

As of 2017 Q4 Bank Of America Corp De has 0% invested in Cleveland Biolabs Inc. Cleveland Biolabs Inc’s shareholder Bank Of Montreal Can owns 31 shares as of 2017 Q4. Furthermore, Blackrock Inc. reported 14,732 shares in Cleveland Biolabs Inc equivalent to 0% of its equity exposure. The Germany-based fund Deutsche Bank Ag have invested about 0% of the investment professional’s stock portfolio in Cleveland Biolabs Inc. The Massachusetts-based fund Geode Capital Management Llc holds 16,688 shares or 0% of their equity exposure.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation.The firm is valued at $31.36 million. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug.Last it reported negative earnings. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand.

$2.78 was the last price.Since May 16, 2017 it’s 101.92% down thus uptrending. CBLI outperformed the S&P 500 by 90.37%.

Geode Mgmt Limited Liability Corporation accumulated 16,688 shs or 0% of the stock. Gp One Trading Limited Partnership holds 0% of its capital in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 68 shs. Wells Fargo And Company Mn reported 150 shs. Blackrock Inc invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Us Commercial Bank De reported 100 shs or 0% of all its holdings. Financial Bank Of Montreal Can owns 31 shs for 0% of their capital. Vanguard stated it has 157,246 shs. Winfield has invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Royal Natl Bank Of Canada reported 0% of its capital in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Renaissance Technologies Ltd invested in 0% or 241,016 shs. Bancorp Of America De invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Panagora Asset Mngmt holds 0% or 10,427 shs in its capital. Stratos Wealth Prtnrs Ltd has invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Deutsche Savings Bank Ag invested in 4 shs. Morgan Stanley invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI).

There’s a significant Cleveland BioLabs, Inc. (NASDAQ:CBLI) news published by Digitaljournal.com. It’s an article titled: “Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress” on May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.